(19)
(11) EP 3 674 314 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
12.07.2023 Bulletin 2023/28

(45) Mention of the grant of the patent:
03.05.2023 Bulletin 2023/18

(21) Application number: 19211432.0

(22) Date of filing: 10.06.2015
(51) International Patent Classification (IPC): 
C07K 14/47(2006.01)
A61K 47/60(2017.01)
A61K 38/00(2006.01)
 A61K 47/54(2017.01)
C07K 19/00(2006.01)
(52) Cooperative Patent Classification (CPC):
C07K 14/47; C07K 2319/30; A61K 38/00; A61K 47/60; A61K 47/542; A61K 38/10; A61P 9/00; A61P 9/04; A61P 9/12

(54)

APELIN POLYPEPTIDES

APELINPOLYPEPTIDE

POLYPEPTIDES D'APÉLINE

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(30) Priority: 10.06.2014 US 201462010322 P

(43) Date of publication of application:
01.07.2020 Bulletin 2020/27

(60) Divisional application:
23171158.1
23171189.6

(62) Application number of the earlier application in accordance with Art. 76 EPC:
15797720.8 / 3155002

(73) Proprietor: Amgen Inc.
Thousand Oaks, CA 91320-1799 (US)

(72) Inventors:
  • HOLDER, Jerry Ryan
    Simi Valley, CA 93065 (US)
  • SWAMINATH, Gayathri
    Brisbane, CA 94005 (US)
  • FROHN, Michael J.
    Thousand Oaks, CA 91362 (US)
  • LANMAN, Brian Alan
    Woodland Hills, CA 91367 (US)
  • REED, Anthony B.
    Newbury Park, CA 91320 (US)
  • MIRANDA, Leslie P.
    Thousand Oaks, CA 91362 (US)
  • ALLEN, John Gordon
    Thousand Oaks, CA 91320-1799 (US)
  • PICKRELL, Alexander J.
    Westlake Village, CA 91361 (US)
  • SIEGMUND, Aaron C.
    Ventura, CA 93003 (US)
  • PENNINGTON, Lewis D
    Arlington, MA 02474 (US)
  • YANG, Bryant
    Agoura Hills, CA 91301 (US)

(74) Representative: Dörries, Hans Ulrich 
df-mp Dörries Frank-Molnia & Pohlman Patentanwälte Rechtsanwälte PartG mbB Theatinerstrasse 16
80333 München
80333 München (DE)


(56) References cited: : 
WO-A1-2012/125408
US-A1- 2014 155 315
 WO-A1-2013/106437
   
  • JEAN-FRANÇOIS MARGATHE ET AL: "Structure-Activity Relationship Studies toward the Discovery of Selective Apelin Receptor Agonists", JOURNAL OF MEDICINAL CHEMISTRY, vol. 57, no. 7, 10 April 2014 (2014-04-10) , pages 2908-2919, XP055257810, US ISSN: 0022-2623, DOI: 10.1021/jm401789v
  • ALEXANDRE MURZA ET AL: "Elucidation of the Structure-Activity Relationships of Apelin: Influence of Unnatural Amino Acids on Binding, Signaling, and Plasma Stability", CHEMMEDCHEM, vol. 7, no. 2, 6 February 2012 (2012-02-06), pages 318-325, XP055072892, ISSN: 1860-7179, DOI: 10.1002/cmdc.201100492
  • ZHANG YANYAN ET AL: "Identifying structural determinants of potency for analogs of apelin-13: Integration of C-terminal truncation with structure-activity", BIOORGANIC & MEDICINAL CHEMISTRY, vol. 22, no. 11, 13 April 2014 (2014-04-13), pages 2992-2997, XP028660063, ISSN: 0968-0896, DOI: 10.1016/J.BMC.2014.04.001
  • A. L. BRAME ET AL: "Design, Characterization, and First-In-Human Study of the Vascular Actions of a Novel Biased Apelin Receptor Agonist", HYPERTENSION., vol. 65, no. 4, 1 April 2015 (2015-04-01), pages 834-840, XP055257809, US ISSN: 0194-911X, DOI: 10.1161/HYPERTENSIONAHA.114.05099
   
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).